Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Faculty of Medicine and Health Sciences
Laboratory Experimental Medicine and Pediatrics (LEMP)
The lancet : international edition. - London, 1823, currens
375(2010):9733, p. 2234-2243
University of Antwerp
Background Diabetes treatments are needed that are convenient, provide eff ective glycaemic control, and do not cause weight gain. We aimed to test the hypothesis that improvement in haemoglobin A1c (HbA1c) achieved with once weekly exenatide was superior to that achieved with insulin glargine titrated to glucose targets. Methods In this 26-week, open-label, randomised, parallel study, we compared exenatide with insulin glargine in adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucoselowering drugs for 3 months or longer. Patients were randomly assigned to add exenatide (2 mg, once-a-week injection) or insulin glargine (once-daily injection, starting dose 10 IU, target glucose range 4·05·5 mmol/L) to their bloodglucose- lowering regimens. Randomisation was with a one-to-one allocation and block size four, stratifi ed according to country and concomitant treatment (70% metformin only; 30% metformin plus sulphonylurea). Participants and clinical investigators were not masked to assignment, but investigators analysing data were. The primary endpoint was change in HbA1c from baseline, and analysis of this outcome was by modifi ed intention to treat for all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, number NCT00641056. Findings 456 patients were randomly allocated to treatment and were included in the modifi ed intention-to-treat analysis (233 exenatide, 223 insulin glargine). Participants who received at least one dose of study drug and for whom baseline and at least one postbaseline measurement of HbA1c were available were included in the primary effi cacy analysis. Change in HbA1c at 26 weeks was greater in patients taking exenatide (n=228; 1·5%, SE 0·05) than in those taking insulin glargine (n=220; 1·3%, 0·06; treatment diff erence 0·16%, 0·07, 95% CI 0·29 to 0·03). 12 (5%) of 233 patients allocated to exenatide and two (1%) of 223 taking insulin glargine discontinued participation because of adverse events (p=0·012). A planned extension period (up to 2·5 years duration) is in progress. Interpretation Once weekly exenatide is an important therapeutic option for patients for whom risk of hypoglycaemia, weight loss, and convenience are particular concerns.